A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease

INTRODUCTION: Cardiovascular (CV) effects of once‐weekly subcutaneous (s.c.) semaglutide 0.5 and 1 mg and dulaglutide 1.5 mg are reported in their respective placebo‐controlled cardiovascular outcome trials (CVOTs), SUSTAIN 6 and REWIND. There is no head‐to‐head CVOT comparing these treatments and h...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Lyndon Marc, Mellbin, Linda, Johansen, Pierre, Lawson, Jack, Paine, Abby, Sandberg, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279621/
https://www.ncbi.nlm.nih.gov/pubmed/34277983
http://dx.doi.org/10.1002/edm2.259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279621/
https://www.ncbi.nlm.nih.gov/pubmed/34277983
http://dx.doi.org/10.1002/edm2.259

Ejemplares similares